medigraphic.com
ISSN 0016-3813 (Print)

2009, Number 4

<< Back Next >>

Gac Med Mex 2009; 145 (4)

II. The economic and social consequences of type 2 diabetes

Silink M

Language: English
References: 17
Page: 290-294
PDF size: 74.20 Kb.


ABSTRACT

Type 2 diabetes involves the interplay of multiple genes and the environment and is currently observed among younger age groups. Universal screening is not a cost-effective strategy since it is preferable to identify at risk groups based on at risk scores. Diabetes is now an epidemic with an estimated 2007 global prevalence among adults of 246 million; by 2025 it will increase to 380 million. For Mexico the 2007 estimated prevalence among adults was 6.1 million and the 2025 projections will be of 10.8 million.
Diabetes is globally responsible for 3.8 million deaths, which exceeds those attributed to HIV/AIDS and malaria combined and for 55.6 million life years lost. The direct health care costs of people with diabetes are generally 2-3 fold greater than for those without the disease and 4-8 fold more if diabetes complications are present. The impact of diabetes on Mexico illustrates an increase of 26% in health care expenditures between the years 2003 -2005. Many of these costs were out-of-pocket expenses. International funding for global action on non-communicable diseases remains very low; in the developing world it is virtually non-existent. Diabetes is one of the world’s most important causes of health-care expenditure, mortality, morbidity and lost economic growth with profound societal and economic implications.


REFERENCES

  1. International Diabetes Federation. Diabetes Atlas. 3rd edition. Brussels, Belgium: International Diabetes Federation; 2006.

  2. DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.

  3. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: the evolving epidemic: the International Diabetes Federation Consensus Workshop. Diabetes Care 2004;27:1798-1811.

  4. International Diabetes Federation. Global guideline for type 2 diabetes. Brussels, Belgium: International Diabetes Federation; 2005.

  5. Zimmet P, Alberti KGMM, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S. IDF Consensus Group. The metabolic syndrome in children and adolescents. An IDF consensus report. Pediatric Diabetes 2007;8:299-306.

  6. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362-2374.

  7. Cruz ML, Weigensberg MJ, Huang TT, Ball G, Shaibi GQ, Goran MI. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab 2004;89:108-113.

  8. Urakami T, Kubota S, Nitadori Y, Harada K, Owada M, Kitagawa T. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care 2005;28:1876-1881.

  9. Yokoyama H, Okudaira M, Otani,T, Sato A, Miura H, Takaike H, et al. Higher incidence of diabetic nephropathy in type 2 diabetes than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int 2000;58(1):302-311.

  10. World Health Organization. Preventing Chronic Diseases. A Vital Investment. World Health Report, 2005. Disponible en http://www.who.int/chp/chronic_disease_report/en/

  11. Arredondo A, Zúniga A. Economic consequences of epidemiological changes in diabetes in middle-income countries. The Mexican case. Diabetes Care 2004;27:104-109.

  12. Arredondo A, Barcelo A. The economic burden of out-of-pocket medical expenditures for patients seeking diabetes care in Mexico. Diabetologia 2007;50:2408-2409.

  13. Finnish Diabetes Association. Development Programme for the Prevention and Care of Diabetes in Finland DEHKO 2000-2010. Disponible en http://www.diabetes.fi/sivu.php?artikkeli_id=831

  14. Tuomilehto J, Lindstrom J, Eriksson J, Valle T, Hamalainen H, Ilanneparikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.

  15. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.

  16. Commission on Social Determinants of Health. Closing the gap in a generation: Health equity through action on the social determinants of health. Geneva: World Health Organization; 2008. Disponible en http://www.phaa.net.au/documents/Closingthegapinageneration.pdf

  17. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al. Disease Control Priorities in Developing Countries. 2nd edition. Oxford University Press/World Bank; 2006. Disponible en http://www.who.int/management/referralhospitals.pdf




2020     |     www.medigraphic.com